Communicate with Supplier? Supplier
Andy Mr. Andy
What can I do for you?
Contact Supplier
Home > Recommended
Renewable Design for β-lactam Antibiotics Cefotaxime For Injection BP/USP 500MG supply to Guinea Suppliers

Renewable Design for β-lactam Antibiotics Cefotaxime For Injection BP/USP 500MG supply to Guinea Suppliers

Renewable Design for β-lactam Antibiotics Cefotaxime For Injection BP/USP 500MG supply to Guinea Suppliers
Contact Now
  • Product Detail
  • Product Tags

We aim to find out high quality disfigurement in the generation and provide the most effective services to domestic and abroad clients wholeheartedly for Cefotaxime For Injection BP/USP 500MG,Cefotaxime For Injection BP 500MG,Cefotaxime For Injection USP 500MG. our merchandise have superior popularity from the whole world as its most competive cost and our most advantage of after-sale assistance for the clients。

Renewable Design for β-lactam Antibiotics Cefotaxime For Injection BP/USP 500MG supply to Guinea Suppliers

INDICATION:

Cefotaxime (cefotaxime for injection) for Injection is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below:

Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Streptococcus pyogenes* (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli, Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae, Proteus mirabilis, Serratia marcescens*, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa).

Genitourinary infections. Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis, Staphylococcus aureus* (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Proteus mirabilis, Proteus vulgaris*, Providencia stuartii, Morganella morganii*, Providencia rettgeri*, Serratia marcescens and Pseudomonas species (including P. aeruginosa).

Gynecologic infections, including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis, Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli, Proteus mirabilis, Bacteroides species (including Bacteroides fragilis*), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum*).

Cefotaxime (cefotaxime for injection) , like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.

Bacteremia/Septicemia caused by Escherichia coli, Klebsiella species, and Serratia marcescens, Staphylococcus aureus and Streptococcus species (including S. pneumoniae).

Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis, Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli, Citrobacter species (including C. freundii*), Enterobacter species, Klebsiella species, Proteus mirabilis, Proteus vulgaris*, Morganella morganii, Providencia rettgeri*, Pseudomonas species, Serratia marcescens, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus species).

Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli, Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus* species) Proteus mirabilis*, and Clostridium species*.

Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes*), Pseudomonas species (including P. aeruginosa*), and Proteus mirabilis*.

Central nervous system infections, e.g., meningitis and ventriculitis, caused by Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae* and Escherichia coli*.


250 MG

500 MG

1 G

1's/box, 500boxes/CTN

10's/box,100boxes/CTN


If you are a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.

If you are a consumer, don't hesitate to contact us about more information for this product.

"So that you can supply you with comfort and enlarge our company, we also have inspectors in QC Workforce and guarantee you our greatest service and item for Cefotaxime For Injection BP/USP 500MG. The product will supply to all over the world, such as: Cocos (Keeling) Islands,Swaziland,Virgin Islands (U.S.). Our factory covers an area of 12000 square meters and has a staff of 200 people among which there are 5 technical executives. We're specialized in producing.We've got rich experience in export. Welcome to contact us and your enquiry is going to be replied as soon as possible.

Buyer Reviews
Other Products

You May Like

Email to this supplier
  • Mr. Andy
  • Your message must be between 20-8000 characters

Home

Phone

Skype

Inquiry